VBL First-in-class MOSPD2 Antibodies Show Potential for Treatment of Multiple Sclerosis May 4, 2020http://ir.vblrx.com/news-releases/news-release-details/vbl-first-class-mospd2-antibodies-show-potential-treatment-cns VBL First-in-class MOSPD2 Antibodies Show Potential for Treatment for CNS Inflammation